Non-invasive therapeutics for anti-osteoporosis treatment and fracture healing are available in both oral and injectable forms. The oral drug segment is expected to capture over 65% of market share by end of 2023, as there is a rising demand for non-invasive therapies. Factors such as the increasing prevalence of needle phobia and needle stick injuries are expected to drive the demand for oral therapeutics
NEWARK, DE / ACCESS Newswire / February 17, 2025 / The global Anti-Osteoporosis Fracture Healing Market is poised for significant growth over the next decade. Valued at USD 15,612.4 million in 2025, the market is projected to reach USD 23,558.5 million by 2035, reflecting a compound annual growth rate (CAGR) of 4.2%.
The market for osteoporosis treatment is expected to experience growth due to the increasing prevalence of the disease and an increase in the number of affected patients. Key players are primarily focusing on the geriatric population which is helping the market to grow. Additionally, prevalence of bone diseases is also contributing to market growth. Increasing research and development expenditure aimed at generating new drugs is further anticipated to induce growth in the market.
The growing awareness about the diagnosis and treatment of osteoporosis is contributing to the expansion of the market. Additionally, an increase in healthcare facilities such as trauma centers is also driving the growth of the anti-osteoporosis therapy and fracture healing market. Increasing investments in research and development activities for generation of drugs and growing awareness about osteoporosis are also adding to the growth of osteoporosis treatment market.
Request a Sample of this Report Now: https://www.futuremarketinsights.com/report-sample#5245502d47422d31303038
Which are Some Prominent Drivers Spearheading the Anti-Osteoporosis Therapy and Fracture Healing Market?
Rising Demand for Non-invasive Therapies to Drive Market Growth
The increasing prevalence of osteoporosis is a key factor driving the global market, as a growing number of patients is expected to drive up demand for drugs and therapy. Additionally, there are no substitutes such as surgery, so the demand for osteoporosis treatment drugs is expected to rise.
The International Osteoporosis Foundation predicted that nearly 50% of global bone fracture incidences will occur in the Asia Pacific region by the end of 2050. The high occurrence and incidence rate of the disease are significant drivers for the market. In addition, the increasing geriatric population is expected to drive market growth in the coming years, although patent expirations of leading brands are likely to considerably slow down the growth rate.
The increasing prevalence of osteopenia and osteogenesis imperfecta (OI) is expected to drive demand for products over the forecast period. The market is also being propelled by the introduction of advanced products and technological advancements.
According to the National Osteoporosis Foundation, calcium deficiency is a major contributor to the increased prevalence of osteoporosis in postmenopausal women. This has become a key driver for anti-osteoporosis therapy and fracture healing demand.
The rising demand for non-invasive therapies is further contributing to the market expansion. Pharmaceutical companies are expected to prioritize improving their production capabilities. The scientific progress made in enhancing product effectiveness and reducing complications has led to increased investment in innovation and the introduction of new products. These efforts are expected to fuel the expansion of the anti-osteoporosis and fracture healing market during the forecast period.
Get the Comprehensive Full Report Now - https://www.futuremarketinsights.com/reports/anti-osteoporosis-therapy-and-fracture-healing-market
Key Takeaways from Market Study:
Projected market size in 2025: USD 15,612.4 million
Projected market size in 2035: USD 23,558.5 million
Expected CAGR from 2025 to 2035: 4.2%
Significant growth driven by rising osteoporosis prevalence and advancements in treatment options
The USA anti-osteoporosis fracture healing industry will be valued a market value of USD 4,847.5 million by 2025, expanding at 2.9% annually, and is set to hit USD 6,451.7 million by 2035.
"The Anti-Osteoporosis Fracture Healing Market is witnessing a transformative phase, driven by demographic shifts and technological advancements. Stakeholders who invest in innovative solutions and patient-centric approaches are well-positioned to capitalize on the emerging opportunities." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Anti-Osteoporosis Fracture Healing MarketDay by Day Opportunities:
The market presents daily opportunities for stakeholders:
Pharmaceutical Companies: Continuous research and development can lead to the introduction of more effective and safer drugs, catering to unmet medical needs.
Healthcare Providers: Implementing comprehensive osteoporosis management programs can enhance patient care and attract a larger patient base.
Investors: Investing in companies focused on osteoporosis therapies offers potential for substantial returns, given the market's projected growth.
Patients: Access to improved therapies increases the chances of better health outcomes and quality of life.
What are the emerging trends in anti-osteoporosis therapies?
Emerging trends in anti-osteoporosis therapies include new drug targets and a shift towards more targeted and personalized treatments.
Here are some key developments:
Emerging Drug Targets: Research is focusing on novel targets such as sclerostin, M-CSF, and RANKL to develop drugs with dual effects of inhibiting bone resorption and promoting bone formation.
Romosozumab and Blosozumab: Romosozumab, a sclerostin antibody, has shown significant increases in bone mineral density (BMD) and reduces the risk of fractures in postmenopausal women with osteoporosis. Blosozumab, another synthetic IgG-type monoclonal sclerostin antibody, has also demonstrated effectiveness in phase II trials.
Anabolic Agents: Abaloparatide, a novel analogue of parathyroid hormone-related protein, is another osteoantimetabolic therapy. Clinical trials have found it to be similarly effective as teriparatide in increasing bone mineral density.
Targeted Delivery Systems: Bisphosphonate-modified nanosystems are being explored as a strategy for addressing osteoporotic conditions.
Personalized Treatment: Recognizing that individual osteoporosis cases have different underlying causes, there's a move towards targeted treatments based on bone biochemical indicators.
Traditional Chinese Medicine (TCM): There's growing interest in TCM and its compound formulas for osteoporosis treatment, which can act on multiple targets and systems. However, more high-quality clinical trials are needed to assess the benefits and risks.
Shift from Oral to Injectable Treatments: There's a growing preference for intravenous and subcutaneous injections over oral prescriptions for osteoporosis treatment.
Focus on Bone-Building Drugs: In patients with severe osteoporosis and high fracture risk, starting with bone-building drugs like teriparatide, followed by anti-resorptive drugs for long-term fracture prevention, may be more beneficial.
Global Therapy Area Industry: Market Forecasts, Competitive Landscape, and Key Trends Across 20+ Countries - https://www.futuremarketinsights.com/industry-analysis/therapy-area
Market's Prime Determinants of Growth, Trends, and Opportunities:
-
Growth Drivers:
Increasing global incidence of osteoporosis
Advancements in drug development and delivery systems
Growing awareness and screening programs for early diagnosis
-
Trends:
Shift towards personalized medicine and targeted therapies
Integration of digital health solutions for patient monitoring
Rising preference for minimally invasive treatment options
-
Opportunities:
Expansion in emerging markets with unmet medical needs
Development of combination therapies to enhance treatment efficacy
Collaborations between pharmaceutical companies and research institutions
Component Insights:
The market is segmented based on drug types, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone analogs, RANK ligand inhibitors, and calcitonin. Among these, bisphosphonates hold a significant share due to their proven efficacy in reducing fracture risk. However, emerging biologics and anabolic agents are gaining traction, offering alternative mechanisms of action and improved patient outcomes.
Key Players of Anti-Osteoporosis Fracture Healing Industry
Amgen Inc.
Eli Lilly and Company
Novartis International AG
Pfizer Inc.
F. Hoffmann La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Merck & Company Inc.
GlaxoSmithKline Plc.
Others
Anti-Osteoporosis Fracture Healing Industry Analysis of Key Segments
By Drug type:
In terms of drug type, the industry is divided into Bisphosphonates (Osteoporosis and Others), Calcitonin (Osteoporosis and Others), Estrogen or Hormone Replacement Therapy (Osteoporosis and Others), Anabolics (Osteoporosis and Others), others (Osteoporosis and Others)
By Route of Administration:
In terms of route of administration, the industry is segregated into oral and injectable.
By Distribution Channel:
In terms of distribution channel, the industry is divided into hospital pharmacies, drug stores, retail pharmacies and E-commerce.
By Region:
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East and Africa (MEA) have been covered in the report.
Explore FMI's Extensive Coverage in the Healthcare Market Insights Domain:
The global allergy treatment market is estimated to account for USD 22.8 billion in 2024. It is anticipated to grow at a CAGR of 7.2% during the assessment period and reach a value of USD 42.7 billion by 2034.
Global sales of allergy diagnostics stand at around USD 6220 million in 2024 and is slated to thrive at a CAGR of 7.7% through 2034. The adoption revenue of allergy diagnostics to attain a valuation of USD 13060.1 million by 2034.
As per Future Market Insights, the IgE allergy blood test market is anticipated to attain a value pool of USD 30 billion by 2023-end. Global demand for IgE allergy blood tests is expected to rise at a CAGR of 5.2% to USD 50 billion in 2033.
The global sales of oral controlled release drug delivery technology are estimated to be worth USD 42.1 billion in 2025 and anticipated to reach a value of USD 84.2 billion by 2035.
The global sales of sphingolipids is estimated to be worth USD 693.9 million in 2025 and anticipated to reach a value of USD 1,145.6 million by 2035.
The global sales of drug formulation are estimated to be worth USD 1.7 trillion in 2025 and are anticipated to reach a value of USD 2.8 trillion by 2035.
The global stoma/ostomy care market holds a valuation of USD 3.8 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 4.9%, and is expected to hold a market value of around USD 6.5 Billion in 2033.
The sales of Patient Positioning Systems have the potential to expand significantly, with a CAGR of 5.4% from 2024 to 2034. The global patient positioning system market size is expected to be valued at USD 508.4 million by 2024. By 2034
The global artificial tears market is expected to register a valuation of USD 3.4 billion in 2024 and further expand at a CAGR of 5.4% to reach a valuation of USD 5.8 billion by 2034.
The global sales of artificial pancreas device systems are estimated to be worth USD 374.3 million in 2025 and are anticipated to reach USD 875.3 million by 2035.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.
Contact Us
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blogs | YouTube
SOURCE: Future Market Insights Inc.
View the original press release on ACCESS Newswire
